Results 151 to 160 of about 7,594,057 (369)
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald+18 more
wiley +1 more source
Trends in bronchoscopic findings over a decade [PDF]
The incidence of lung cancer in Maltese males is higher than that in females. However trends in Maltese and other foreign populations indicate a substantial recent increment in the diagnosis of lung cancer in women.
Agius, Maria+4 more
core
Geographical Distribution of Disease: With Special Reference to Cancer of the Lung and Stomach in Wales [PDF]
G. Melvyn Howe
openalex +1 more source
EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche+8 more
wiley +1 more source
Chinese Anti-Cancer Association, Lung Cancer Study Group of Committee of Oncopathology+2 more
doaj +1 more source
The Place of Tobacco in the Etiology of Lung Cancer [PDF]
Edward Hammond
openalex +1 more source
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner+6 more
wiley +1 more source
A DIA‐MS‐based proteomics analysis of serum samples from GB patients and healthy controls showed that high levels of IL1R2 and low levels of CRTAC1 and HRG in serum are associated with poor survival outcomes for GB patients. These circulating proteins could serve as biomarkers for the prediction of outcome in patients with GB.
Anne Clavreul+11 more
wiley +1 more source